Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service sleep apnea & airway implants cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (12 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 11 | 28% |
| 2021 | 1 | 34 | 39% |
| 2022 | 1 | 63 | 35% |
| 2023 | 1 | 109 | 38% |
| 2024 | 2 | 127 | 39% |
| 2025 from claims | – | 68 55–80 | 40% |
| 2026 forecast | – | 76 59–95 | 39% |
| 2027 forecast | – | 83 62–110 | 40% |
| 2028 forecast | – | 92 65–126 | 40% |
| 2029 forecast | – | 101 68–144 | 40% |
| 2030 forecast | – | 111 73–165 | 40% |
Hypoglossal nerve stimulation and upper airway procedures. Professional codes (what the surgeon bills): CPT 64582, 64583, 64584, 42145, 41530.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Massachusetts; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 8 | 263+58%/yr | +58%/yr | 0.2 | 0% | 300 in 2030+2.1%/yr |
| New York | 2 | 146+38%/yr | +38%/yr | 0.1 | 19% | 160 in 2030+1.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 25 | 2,622−3.9%/yr | −3.9%/yr | 2.80.8× | 53% | 3,080 in 2030+2.7%/yr |
| Ear tubes & middle ear surgery | 0 | 237−3.1%/yr | −3.1%/yr | 0.31.0× | 36% | 130 in 2030−10%/yr |
| Cochlear implants | 4 | 130+3.6%/yr | +3.6%/yr | 0.11.6× | 0% | 220 in 2030+9.5%/yr |
Sleep apnea & airway implants in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with Pennsylvania
Inspire Medical Systems leads with 95% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 9 companies reported engagement with Massachusetts’s surgeons worth $84K in consulting, speaking, meals and travel tied to these products, about $42K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 18 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.